Brain tumor, treatment

Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995 345 1008-1012. 

Primary and metastatic brain tumors Treatment of acute intermittent porphyria, hereditary coproporphyria, and variegata porphyria Precocious puberty AIDS AIDS... 

Brem, H., Piantadosi, S., Burger, P. C., Walker, M., Selker, R., Vick, N. A., Black, K., Sisti, M., Brem, S. and Mohr, G., Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable p>olymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group, lancet, 345(8956), 1008,1995. 

Cancer chemothCTapeutic agents as a rule poorly penetrate the blood brain barrier. Brain tumors are thus not readily treatable by chemotherapy. Diaziquone (at one time known as AZQ) is an exception to this generalization. Treatment of chloranil (213) with the anion from urethane gives intermediate 214, probably by an addition elimination scheme. Displacement of the remaining halogen with aziridine yields diaziquone (215) [.55J. 

Lomustine (2-chlorethyl-3 cyclohexyl-1 -nutrosourea, CCNU, Fig 3) is a nitrosourea for oral application. It is used for the treatment of Hodgkin s lymphomas, brain tumors and bronchial carcinomas at a dose of 3.5 mg/kg (130 mg/m2) repeated in 6-8 weeks intervals. 

Temozolomide crosses the blood brain barrier and can be used for the treatment of brain tumors (e.g., glioblastoma multiforme). The most common side effects are nausea and vomiting. 

Brain scans are used to study epiiepsy, brain tumors, strokes, Aizheimer s disease, and mentai iiiness. Each of these disorders generates a unique brain activity pattern that differs from the pattern seen in normai brains. Physicians interpret these patterns both for diagnosis and to indicate appropriate treatment. 

In addition to their inherent self-sustaining properties, brain tumor stem cells may be more resistant to chemotherapy and radiation therapy than other tumor cells. Bao et al. (2006) found glioma stem cells (CD133+) were relatively radioresistant compared to CD133- tumor cells and preferentially activated the DNA damage checkpoint response. This relative resistance to standard treatment approaches of tumor stem cells compared to the majority of other cells within a tumor may underlie our current inability to cure patients with aggressive brain tumors such as glioblastoma. 

Boro nophenyl) alanine (BPA) is a practical boron compound which is clinically used for the treatment of not only malignant melanoma but also of brain tumors, in neutron capture therapy (Scheme 1-40) [105, 152, 153]. Although (pinacolato)di-boron (82) is an excellent reagent to afford the corresponding boronate in 88% yield, it strongly resists the hydrolysis to arylboronic acids. Alternatively, the 1,3-diphenyl-propanediol ester (85) is more convenient to deprotect the diol moiety by catalytic hydrogenolysis [105]. 

Much attention has recently been focused on organoboronic acids and their esters because of their practical usefulness for synthetic organic reactions including asymmetric synthesis, combinatorial synthesis, and polymer synthesis [1, 3, 7-9], molecular recognition such as host-guest compounds [10], and neutron capture therapy in treatment of malignant melanoma and brain tumor ]11]. New synthetic procedures reviewed in this article wiU serve to find further appHcations of organoboron compounds. 

Metal-texaphyrin complexes such as 55 selectively accumulate in tumor cells (240) (see Section III). Complex 55 readily undergoes aone-electron reduction (Ei/2 = 0.08 V vs NHE), forming a free radical which is capable of damaging DNA. Because of the high electron affinity of 55, it may prolong the lifetime of HO- radicals formed by radiolysis of water. Complex 55 is now in phase II clinical trials for the treatment of brain tumors and lung, head, neck, and pancreatic cancer. 

Several gene therapies have received orphan drug designation these are treatments for cystic fibrosis, Gaucher disease, and metastatic brain tumor. 

CEO, Stephen Hoffman and VP for clinical studies, Michael Gerber of Alios Therapeutics guided RSR 13 through a series of phase-one and phase-two clinical trials for radiation treatment of brain tumors and for potential use in cardiopulmonary bypass surgery [46, 51-55]. Considering the cost of running a phase-three clinical trial, only one was possible. The very positive phase-two results for use of RSR 13 to treat metastatic brain cancer provided the impetus for selecting that indication for a phase-three trial. 

The study of the Central Nervous System (CNS) is the primary clinical indication for the use of extracellular Gd(III) agents. The majority of these pathologies are brain tumors, and three quarters of them are represented by metastases occurring in patients undergoing treatment for systemic cancer (Fig. 1). Other brain diseases, such as multiple sclerosis and cerebral injuries can be also investigated by contrast-enhanced MRI. 

Dexamethasone Testing of adrenal cortical hyperfunction cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Tnamc/no/one Treatment of pulmonary emphysema where bronchospasm or bronchial edema plays a significant role, and diffuse interstitial pulmonary fibrosis (Hamman-Rich syndrome) in conjunction with diuretic agents to induce a diuresis in refractory CHF and in cirrhosis of the liver with refractory ascites and for postoperative dental inflammatory reactions. 

IR concentrated oral solution and tablets/suppositories - Respiratory insufficiency or depression severe CNS depression attack of bronchial asthma heart failure secondary to chronic lung disease cardiac arrhythmias increased intracranial or CSF pressure head injuries brain tumor acute alcoholism delirium tremens convulsive disorders after biliary tract surgery suspected surgical abdomen surgical anastomosis concomitantly with MAOIs or within 14 days of such treatment paralytic ileus. 

Early clinical studies clearly demonstrated that cisplatin could be administered safely and concurrently with radiation therapy (73-75). Early clinical trials that demonstrated the promise of the combination of cisplatin and radiation therapy included the treatment of brain tumors (76,77), head and neck tumors (78), malignant melanoma (79), and bladder cancer (80). Early clinical trial integrating carboplatin administration with radiation therapy was carried out in patients with locally advanced nonsmall cell lung cancer (NSCLC) (81). A hypothesis put forth by Coughlin and colleagues (81) was that the best clinical outcomes would be achieved with the combination of cisplatin and radiation therapy in tumors that were responsive to cisplatin. 

---